Coronavirus vaccine stocks to watch

Here are the key companies involved in the COVID-19 vaccine race, their share prices and how to invest in them.

Updated

Fact checked

According to the World Health Organization (WHO), there are 48 candidate vaccines in clinical evaluation and the race is on to find a successful one – or several. Usually vaccines take years to create and test, but with the urgency to create this one, many countries are allowing phases to be conducted simultaneously.

As any company knows, successful results will mean a rise in its stock price. We’ve compiled some of the companies currently in the race to create a vaccine and what phase they’re currently in.

The different phases of vaccine creation

  • Phase one. This includes testing the candidate on a small group to find out if there are any adverse reactions to it.
  • Phase two. This phase tests whether the vaccine is safe for humans. The potential vaccine is tested on a larger group.
  • Phase three. In this phase, the candidates are tested on a much larger scale with tens of thousands of people.
  • Regulation. If all three phases are successful then it gets put to regulators. The regulation processes tend to differ between countries and have been slightly different due to the severity of COVID-19.

Who’s winning the coronavirus vaccine race?
There are a few companies currently in the lead, such as Pfizer and BioNTech, Moderna and University of Oxford and AstraZeneca. All of these companies have stated that their vaccines are more than 50% effective.

Check out the coronavirus vaccine race below.

What does a vaccine mean for investors?

Companies currently in phase 3

Johnson & Johnson – Ad26.COV2.S

Johnson & Johnson announced in September that it has launched its phase three trials for its COVID-19 vaccine. The phase one trial started in the US and Belgium in mid-July. It plans to have its first batches available for use in early 2021 and aims to provide more than 1 billion doses of its vaccine each year.

Novavax – NVX-CoV2373

Novavax‘s candidate started human trials in July which suggested that it is safe and effective. In September, it announced that it has initiated a phase three study for the potential vaccine.

Novavax has already been awarded a contract from the US Department of Defense to manufacture the vaccine.

University of Oxford/ AstraZeneca – ChAdOx1 nCoV-19

This candidate hasn’t reported any adverse reactions on humans so far. It says the volunteers have responded in the same way as animals that have been protected from the virus. It is currently being trialled on tens of thousands of volunteers

AstraZeneca will be responsible for manufacturing and distributing the vaccine.

Over 2 billion doses have been ordered by the UK, US, Europe and India.

Sinovac – CoronaVac

Started work in January. Phase 1 and 2 trials were made on 743 people and no adverse side effects have been reported.

It’s started on phase three, but phase two is not expected to be finished until the end of 2020.
Phase three will test the vaccine on almost 9,000 healthcare professionals in Brazil.

Primary results from phase three should be ready in September 2021, while the study is due to be finished by October 2021.

Sinopharm

The China National Pharmaceutical Group has been working on a vaccine developed by the Beijing Institute of Biological Products and the Wuhan Institute of Biological Products.
Chairman Liu Jingzhen has reportedly already injected himself with the vaccine before clinical trials began.

It’s started working on phase three with thousands of volunteers in the UAE.

It’s been suggested by the chairman that Sinopharm will be ready before the end of the year.

HKG: 1099

Moderna – mRNA-1273

Moderna is working with the National Institute of Allergy and Infectious Diseases (NIAID). It was one of the first to get started on the vaccine. Phase two is currently in motion and has had positive results so far.

Phase 3 hasn’t yet started but has been approved to include 30,000 volunteers. It is estimated to be completed in October 2022 and the company plans to deliver 500 million doses per year.

BioNTech, Fosun Pharma and Pfizer

Some good news broke in November about BioNtech, Pfizer and Fosun Pharma’s vaccine which could be ready before the end of 2020. Two of its candidates have been through preliminary trials, one of which went on to do phase 2 and 3 trials on up to 30,000 volunteers. Pfizer and BioNTech plan to supply up to 100 million doses before the end of 2020 if they get regulatory approval.

The companies already have deals signed with numerous countries including the US, Canada, Japan and the UK.

SHA: 600196

Companies currently in phase 2

Cadila Healthcare (Zydus Cadila) – ZyCov-D

The potential vaccine has so far been found to be safe, and the company is due to start phase three in December 2020. This candidate is a 3-dose vaccine and the company plans to begin with the manufacturing of 100 million doses.

CanSino Biologics – Ad5-nCOV

CanSino Biologics has finished its phase 2 trials on more than 500 people in Wuhan, China. It is looking to test the potential candidate on more than 400,000 people in phase 3.

HKG: 6185

Anhui Zhifei Longcom Biopharmaceutical

Anhui Zhifei Longcom is working with the Chinese Academy of Sciences to create a vaccine. It started on phase 1 trials in May and started on phase 2 on 900 volunteers in July.
300122.SZ

Companies in phase 1

The Institute of Medical Biology of the Chinese Academy of Medical Science

The Institute of Medical Biology of the Chinese Academy of Medical Science has already been through phase 1 and has nearly 400 participants lined up for a phase 2 trial. It plans to finish this in November 2021.

Inovio Pharmaceuticals – INO-4800

Inovio Pharmaceuticals has already done some studies on animals and reported successful results and its phase 1 trial on 40 people has good results with an immune response in 94% of patients. It is working with the International Vaccine Institute.

AnGes

AnGes has partnered with Osaka University and Takara Bio to produce a vaccine. It is currently conducting phases one and two with its product.

TYO: 4563

Genexine – GX-19

Genexine announced in June that it has approval from South Korea’s Ministry of Food and Drug Safety for a phase one and two trial.

KOSDAQ: 095700

Bharat Biotech – Coro-Flu

Coro-Flu has already been ruled safe for humans under phase one and two trials. It’s now being adapted for coronavirus.
BSE. NSE

British American Tobacco

One of the most unexpected companies in this list – British American Tobacco – is a tobacco maker. It has a US biotech arm which is using “tobacco plant technology” to create a potential vaccine. The product is awaiting US Food and Drug Administration authorisation to carry out phase one human clinical trials.

Arcturus – LUNAR-COV19

Arcturus’s candidate is currently being tested with the Duke NUS Medical School. It has already signed a deal to supply its vaccine to Israel if it is successful. It’s currently in phase one and two clinical trials.

Compare investment services

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Your first 100 trades are free with Fineco, T&Cs apply.
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
Degiro Share Dealing
£1.75 + 0.022% (max £5.00)
£1.75 + 0.022% (max £5.00)
Portfolio transfer fees (in & out)
Degiro is widely seen as one of the best low-cost share brokers, for people who are looking to trade regularly. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Legal & General stocks and shares ISA
Legal & General stocks and shares ISA
£100 or £20 a month
0.61%
N/A
Legal & General is a big financial services company which offers insurance, lifetime mortgage, pensions and stocks and shares ISAs. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
Penfold
Penfold
No minimum
4 portfolios
0.75-0.88%
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

This article offers general information about investing and the stock market, but should not be construed as personal investment advice. It has been provided without consideration of your personal circumstances or objectives. It should not be interpreted as an inducement, invitation or recommendation relating to any of the products listed or referred to. The value of investments can fall as well as rise, and you may get back less than you invested. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please get financial advice. The author holds no positions in any share mentioned.

More guides on Finder

  • Coronavirus: Stocks to watch in Lockdown 2

    The UK is went back into lockdown on Thursday 5 November. We’ve compiled some lockdown stocks that might see some growth over the next month.

  • Artificial intelligence stocks

    You might think that AI is just something you’ve seen in Black Mirror or Westworld, but it’s slowly working its way into our day to day lives. Find out how you can invest in it.

  • Best big data stocks to invest in

    Big data is a large set of data, and it’s not named big for nothing! Discover how you can invest in companies that source and manage this type of data.

  • Cloud stocks | Top cloud companies to invest in 2020

    Cloud computing stocks have skyrocketed during 2020. In this article we look at the best performers, how to invest in them, and also take a quick look at cloud computing ETFs for you to invest in too.

  • How to invest in the FTSE 100

    The FTSE 100 is the UK’s most famous stock index. Here’s how you can invest in it today.

  • Brexit currency fallout: Exchange Rate Tracker

    Follow the major events of Brexit and how they might affect you with our interactive currency exchange rate tracker.

  • How to invest in cotton

    Ever thought about investing in cotton? Here’s our guide to the investments options at your disposal, the benefits of investing in cotton, as well as the possible risks.

  • How to invest in gas

    Learn how to invest in natural gas, and about gas’s historical performance as an investment. Find out all the need-to-knows with our extensive guide.

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site